Two immune blockers for ankylosing spondylitis
Treatments studied
Part of Bones, joints & muscles clinical trials.
This study tests whether combining two types of immune-blocking drugs (an IL-17 inhibitor and a TNF inhibitor) works better than either alone for treating ankylosing spondylitis. It is for people whose symptoms are not well controlled with NSAIDs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old
- You have a confirmed diagnosis of ankylosing spondylitis (a type of arthritis that affects the spine)
- You have tried at least two different NSAID pain relievers (like ibuprofen) for at least 4 weeks total and they didn't help enough, or you couldn't take them
- You have active disease with significant back pain and stiffness
- You must be willing to take the study drugs (adalimumab and secukinumab) and follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
This study tests a new medication (called 608) for adults with active ankylosing spondylitis (AS). It aims to see if the drug can reduce AS symptoms and improve quality of life.
This study compares two types of biologic drugs (IL-17 inhibitors vs. anti-TNF drugs) in people with ankylosing spondylitis (a form of arthritis affecting the spine) who have already tried standard treatments. The goal is to see which drug works better for controlling symptoms.
This trial tests a new oral medication called LNK01001 for adults with active ankylosing spondylitis. It aims to reduce pain, stiffness, and inflammation when standard NSAID treatments no longer help.
This trial is testing the safety of a medicine called secukinumab in adults with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It may be a good option if you have this condition and want to help researchers learn more about how safe this treatment is for Indian patients.
This trial tests whether stem cells from donated bone marrow can reduce inflammation and pain in ankylosing spondylitis, a condition that causes the spine to become stiff and inflamed. Researchers will monitor how safe and effective this treatment is for eligible patients.
Hear when a new Ankylosing Spondylitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.